Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mechel reported for 6 months of 2023 by IFRS

8/29/23 MTLR

MMK reported for 6 months of 2023 by IFRS

8/29/23 MAGN

MKB reported for 6 months of 2023 by IFRS

8/29/23 CBOM

RusHydro reported for 6 months of 2023 by IFRS

8/29/23 HYDR

TNS Energo Voronezh reported for 6 months of 2023 by IFRS

8/29/23 VRSB

Buryatzoloto reported for 6 months of 2023 by IFRS

8/29/23 BRZL

ZIL reported for 6 months of 2023 by IFRS

8/29/23 ZILL

KGC reported for 6 months of 2023 by RAS

8/29/23 KGKC

"Mechel summarized its results in the first half of the year

8/29/23 MTLR

Polyus in the first half of the year increased gold production by 36%

8/29/23 PLZL